Growth Hormone Treatment on Phosphocreatine Recovery in Obesity
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Obesity is associated with reduced growth hormone (GH) secretion. Reduced GH secretion in
obesity is associated with increased cardiovascular disease risk. However, it is not yet
known how reduced GH increases cardiovascular disease risk in obesity. The investigators
hypothesize that reduced GH contributes to dysfunction of the mitochondria. Therefore, the
investigators hypothesize that treatment of obese subjects with reduced GH secretion with GH
will improve mitochondrial function and that this improvement in mitochondrial function will
contribute, in part, to the effects of GH to improve metabolic parameters in obesity. The
investigators propose to study skeletal muscle mitochondria in obese subjects with reduced GH
secretion using magnetic resonance spectroscopy and muscle biopsies before and after
treatment with GH.